In a first, FDA approves blood test for early Alzheimer’s diagnosis

FDA clears first blood test for alzheimer’s disease, opening doors for earlier, easier diagnosis

WASHINGTON, D.C.: In a landmark move that may reshape the future of Alzheimer’s detection, the United States Food and Drug Administration (FDA) has officially approved the first-ever blood test for Alzheimer’s disease, providing a major breakthrough in early diagnosis. The test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, developed by Fujirebio Diagnostics, Inc., is designed to detect the presence of beta-amyloid and tau proteins—two biomarkers strongly associated with Alzheimer’s pathology—in a simple blood sample.

A simpler, faster path to detection

Until now, confirming an Alzheimer’s diagnosis required invasive procedures such as spinal taps or expensive PET scans to assess these biomarkers in cerebrospinal fluid (CSF). The newly approved blood test significantly reduces both discomfort and cost, allowing wider access to early testing—particularly for those who previously avoided evaluation due to fear or financial limitations.

“This test represents a significant advancement in simplifying the evaluation of patients showing early memory symptoms,” said Dr. Gediminas Gliebus, director of cognitive neurology at Marcus Neuroscience Institute.

How the Alzheimer’s blood test works

The Lumipulse test evaluates the ratio between phosphorylated tau (pTau 217) and beta-amyloid 1-42 in plasma. A disruption in this balance signals the likely formation of amyloid plaques, a key indicator of Alzheimer’s disease.

“It’s like identifying the culprits causing brain damage,” explains Dr. Manisha Parulekar, co-director at Hackensack University Medical Center. “Beta-amyloid forms sticky clumps between neurons, while tau gets twisted inside them, disrupting communication and nutrient flow.”

Advantages over traditional CSF testing

• Minimally invasive: Requires only a standard blood draw
• Cost-effective: Avoids costly imaging or lumbar puncture
• Broad accessibility: Can potentially be administered in primary care
• Encourages early intervention: Detects changes even before full-blown symptoms appear

According to Gliebus, only 20% of patients may still require follow-up CSF or PET tests, marking a sharp decline in dependence on invasive diagnostics.

Caution and limitations

While the new test is promising, experts caution against its use as a standalone screening tool, especially in general practice.

“This is not a screening test—it’s a diagnostic aid,” said Dr. Bhavana Patel, assistant professor of neurology at the University of Florida. “Interpretation must be done by specialists, and false positives or negatives remain possible.”

Dr. Clifford Segil, a neurologist in private practice, warned against over-reliance:

“These biomarkers are known to yield false results in clinical settings. Diagnosis should still rely on medical history, cognitive exams, and expert evaluation.”

A new era for Alzheimer’s care?

Despite some unanswered questions, the medical community largely views this approval as a major step toward earlier diagnosis, better disease management, and broader access to treatment opportunities.

“The lower cost and convenience of a blood test can help underserved communities receive an earlier diagnosis,” said Parulekar. “But clinical context is still key.”

As dementia cases are expected to triple by 2050, innovations like the Lumipulse test could transform global Alzheimer’s care—helping millions receive help before it’s too late.

JOIN NOW: Medical News Pakistan WhatsApp Channel for exclusive alerts, expert opinions, and real-time coverage on public health and new breakthroughs in medical science.